Last reviewed · How we verify
Azilsartan medoxomil - chlorthalidone
Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.
Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension.
At a glance
| Generic name | Azilsartan medoxomil - chlorthalidone |
|---|---|
| Also known as | TAK-491CLD, Edarbyclor |
| Sponsor | Takeda |
| Drug class | Angiotensin II receptor blocker / Thiazide-like diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor) / Sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and other tissues, causing vasodilation and reduced blood pressure. Chlorthalidone is a long-acting thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting sodium and water excretion to further reduce blood volume and blood pressure. The combination provides complementary antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperuricemia
- Hypokalemia
- Hyperglycemia
- Hypotension
Key clinical trials
- A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.
- A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone (PHASE3)
- Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease (PHASE3)
- Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension (PHASE3)
- Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension (PHASE3)
- Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azilsartan medoxomil - chlorthalidone CI brief — competitive landscape report
- Azilsartan medoxomil - chlorthalidone updates RSS · CI watch RSS
- Takeda portfolio CI